ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Virus like Particle (VLP) Vaccines Market Research Report 2026
Published Date: 2026-01-23
|
Report Code: QYRE-Auto-6Y18777
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Virus like Particle VLP Vaccines Market Research Report 2024
BUY CHAPTERS

Global Virus like Particle (VLP) Vaccines Market Research Report 2026

Code: QYRE-Auto-6Y18777
Report
2026-01-23
Pages:119
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Premas Biotech
BioAgilytix
Coriolis
Charles River Laboratories
VBI Vaccines Inc
Creative Biostructure
Wuxi Biologics
Creative Diagnostics
Shanghai Bovax Biotechnology Co., Ltd.
Junshi Biosciences
Luye Pharma Group
Chengdu Kanghua Biological Products Co.,Ltd.
AstraZeneca Group (Icosavax)

Virus like Particle (VLP) Vaccines Market

The global Virus like Particle (VLP) Vaccines market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Virus like Particle (VLP) Vaccines competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Virus-Like Particles (VLPs) are an emerging vaccine technology. VLPs consist of protein shells comprising outer proteins specific to the virus in question. VLPs are more representative of how viral antigens are presented in vivo. While they are highly immunogenic, they are non-infectious as they lack the core genetic material of the virus. Another essential advantage of VLPs is that they more effectively activate critical aspects of the immune response to achieve potent immune stimulation and provide immunological memory. VLP-based vaccines have also shown to provide effective protection and are currently used for several diseases.
The North American market for Virus like Particle (VLP) Vaccines is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Virus like Particle (VLP) Vaccines is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Virus like Particle (VLP) Vaccines include AstraZeneca Group (Icosavax), Premas Biotech, BioAgilytix, Coriolis, Charles River Laboratories, VBI Vaccines Inc, Creative Biostructure, WuXi Biologics, Creative Diagnostics, Shanghai Bovax Biotechnology Co., Ltd., etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Virus like Particle (VLP) Vaccines market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Virus like Particle (VLP) Vaccines. The Virus like Particle (VLP) Vaccines market size, estimates, and forecasts are provided in terms of sales volume (K Dose) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Virus like Particle (VLP) Vaccines market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Virus like Particle (VLP) Vaccines manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Virus like Particle (VLP) Vaccines Market Report

Report Metric Details
Report Name Virus like Particle (VLP) Vaccines Market
Segment by Type
  • Prophylactic Vaccine
  • Therapeutic Vaccine
by Application
  • Hepatitis B Virus (HBV)
  • Human Papillomavirus (HPV)
  • Hepatitis E Virus (HEV)
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company AstraZeneca Group (Icosavax), Premas Biotech, BioAgilytix, Coriolis, Charles River Laboratories, VBI Vaccines Inc, Creative Biostructure, WuXi Biologics, Creative Diagnostics, Shanghai Bovax Biotechnology Co., Ltd., Junshi Biosciences, Luye Pharma Group, Chengdu Kanghua Biological Products Co., Ltd.
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Virus like Particle (VLP) Vaccines manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Virus like Particle (VLP) Vaccines sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

Who are the main players in the Virus like Particle (VLP) Vaccines Market report?

Ans: The main players in the Virus like Particle (VLP) Vaccines Market are AstraZeneca Group (Icosavax), Premas Biotech, BioAgilytix, Coriolis, Charles River Laboratories, VBI Vaccines Inc, Creative Biostructure, WuXi Biologics, Creative Diagnostics, Shanghai Bovax Biotechnology Co., Ltd., Junshi Biosciences, Luye Pharma Group, Chengdu Kanghua Biological Products Co., Ltd.

What are the Application segmentation covered in the Virus like Particle (VLP) Vaccines Market report?

Ans: The Applications covered in the Virus like Particle (VLP) Vaccines Market report are Hepatitis B Virus (HBV), Human Papillomavirus (HPV), Hepatitis E Virus (HEV), Other

What are the Type segmentation covered in the Virus like Particle (VLP) Vaccines Market report?

Ans: The Types covered in the Virus like Particle (VLP) Vaccines Market report are Prophylactic Vaccine, Therapeutic Vaccine

1 Virus like Particle (VLP) Vaccines Market Overview
1.1 Product Definition
1.2 Virus like Particle (VLP) Vaccines by Type
1.2.1 Global Virus like Particle (VLP) Vaccines Market Value by Type: 2025 vs 2032
1.2.2 Prophylactic Vaccine
1.2.3 Therapeutic Vaccine
1.3 Virus like Particle (VLP) Vaccines by Application
1.3.1 Global Virus like Particle (VLP) Vaccines Market Value by Application: 2025 vs 2032
1.3.2 Hepatitis B Virus (HBV)
1.3.3 Human Papillomavirus (HPV)
1.3.4 Hepatitis E Virus (HEV)
1.3.5 Other
1.4 Global Virus like Particle (VLP) Vaccines Market Size Estimates and Forecasts
1.4.1 Global Virus like Particle (VLP) Vaccines Revenue 2021–2032
1.4.2 Global Virus like Particle (VLP) Vaccines Sales 2021–2032
1.4.3 Global Virus like Particle (VLP) Vaccines Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Virus like Particle (VLP) Vaccines Market Competition by Manufacturers
2.1 Global Virus like Particle (VLP) Vaccines Sales Market Share by Manufacturers (2021–2026)
2.2 Global Virus like Particle (VLP) Vaccines Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Virus like Particle (VLP) Vaccines Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Virus like Particle (VLP) Vaccines, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Virus like Particle (VLP) Vaccines, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Virus like Particle (VLP) Vaccines, Product Types and Applications
2.7 Global Key Manufacturers of Virus like Particle (VLP) Vaccines, Date of Entry into the Industry
2.8 Global Virus like Particle (VLP) Vaccines Market Competitive Situation and Trends
2.8.1 Global Virus like Particle (VLP) Vaccines Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Virus like Particle (VLP) Vaccines Players Market Share by Revenue
2.8.3 Global Virus like Particle (VLP) Vaccines Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Virus like Particle (VLP) Vaccines Market Scenario by Region
3.1 Global Virus like Particle (VLP) Vaccines Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Virus like Particle (VLP) Vaccines Sales by Region: 2021–2032
3.2.1 Global Virus like Particle (VLP) Vaccines Sales by Region: 2021–2026
3.2.2 Global Virus like Particle (VLP) Vaccines Sales by Region: 2027–2032
3.3 Global Virus like Particle (VLP) Vaccines Revenue by Region: 2021–2032
3.3.1 Global Virus like Particle (VLP) Vaccines Revenue by Region: 2021–2026
3.3.2 Global Virus like Particle (VLP) Vaccines Revenue by Region: 2027–2032
3.4 North America Virus like Particle (VLP) Vaccines Market Facts & Figures by Country
3.4.1 North America Virus like Particle (VLP) Vaccines Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Virus like Particle (VLP) Vaccines Sales by Country (2021–2032)
3.4.3 North America Virus like Particle (VLP) Vaccines Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Virus like Particle (VLP) Vaccines Market Facts & Figures by Country
3.5.1 Europe Virus like Particle (VLP) Vaccines Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Virus like Particle (VLP) Vaccines Sales by Country (2021–2032)
3.5.3 Europe Virus like Particle (VLP) Vaccines Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Virus like Particle (VLP) Vaccines Market Facts & Figures by Region
3.6.1 Asia Pacific Virus like Particle (VLP) Vaccines Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Virus like Particle (VLP) Vaccines Sales by Region (2021–2032)
3.6.3 Asia Pacific Virus like Particle (VLP) Vaccines Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Virus like Particle (VLP) Vaccines Market Facts & Figures by Country
3.7.1 Latin America Virus like Particle (VLP) Vaccines Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Virus like Particle (VLP) Vaccines Sales by Country (2021–2032)
3.7.3 Latin America Virus like Particle (VLP) Vaccines Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Virus like Particle (VLP) Vaccines Market Facts & Figures by Country
3.8.1 Middle East and Africa Virus like Particle (VLP) Vaccines Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Virus like Particle (VLP) Vaccines Sales by Country (2021–2032)
3.8.3 Middle East and Africa Virus like Particle (VLP) Vaccines Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Virus like Particle (VLP) Vaccines Sales by Type (2021–2032)
4.1.1 Global Virus like Particle (VLP) Vaccines Sales by Type (2021–2026)
4.1.2 Global Virus like Particle (VLP) Vaccines Sales by Type (2027–2032)
4.1.3 Global Virus like Particle (VLP) Vaccines Sales Market Share by Type (2021–2032)
4.2 Global Virus like Particle (VLP) Vaccines Revenue by Type (2021–2032)
4.2.1 Global Virus like Particle (VLP) Vaccines Revenue by Type (2021–2026)
4.2.2 Global Virus like Particle (VLP) Vaccines Revenue by Type (2027–2032)
4.2.3 Global Virus like Particle (VLP) Vaccines Revenue Market Share by Type (2021–2032)
4.3 Global Virus like Particle (VLP) Vaccines Price by Type (2021–2032)
5 Segment by Application
5.1 Global Virus like Particle (VLP) Vaccines Sales by Application (2021–2032)
5.1.1 Global Virus like Particle (VLP) Vaccines Sales by Application (2021–2026)
5.1.2 Global Virus like Particle (VLP) Vaccines Sales by Application (2027–2032)
5.1.3 Global Virus like Particle (VLP) Vaccines Sales Market Share by Application (2021–2032)
5.2 Global Virus like Particle (VLP) Vaccines Revenue by Application (2021–2032)
5.2.1 Global Virus like Particle (VLP) Vaccines Revenue by Application (2021–2026)
5.2.2 Global Virus like Particle (VLP) Vaccines Revenue by Application (2027–2032)
5.2.3 Global Virus like Particle (VLP) Vaccines Revenue Market Share by Application (2021–2032)
5.3 Global Virus like Particle (VLP) Vaccines Price by Application (2021–2032)
6 Key Companies Profiled
6.1 AstraZeneca Group (Icosavax)
6.1.1 AstraZeneca Group (Icosavax) Company Information
6.1.2 AstraZeneca Group (Icosavax) Description and Business Overview
6.1.3 AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Product Portfolio
6.1.5 AstraZeneca Group (Icosavax) Recent Developments/Updates
6.2 Premas Biotech
6.2.1 Premas Biotech Company Information
6.2.2 Premas Biotech Description and Business Overview
6.2.3 Premas Biotech Virus like Particle (VLP) Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Premas Biotech Virus like Particle (VLP) Vaccines Product Portfolio
6.2.5 Premas Biotech Recent Developments/Updates
6.3 BioAgilytix
6.3.1 BioAgilytix Company Information
6.3.2 BioAgilytix Description and Business Overview
6.3.3 BioAgilytix Virus like Particle (VLP) Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 BioAgilytix Virus like Particle (VLP) Vaccines Product Portfolio
6.3.5 BioAgilytix Recent Developments/Updates
6.4 Coriolis
6.4.1 Coriolis Company Information
6.4.2 Coriolis Description and Business Overview
6.4.3 Coriolis Virus like Particle (VLP) Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Coriolis Virus like Particle (VLP) Vaccines Product Portfolio
6.4.5 Coriolis Recent Developments/Updates
6.5 Charles River Laboratories
6.5.1 Charles River Laboratories Company Information
6.5.2 Charles River Laboratories Description and Business Overview
6.5.3 Charles River Laboratories Virus like Particle (VLP) Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Charles River Laboratories Virus like Particle (VLP) Vaccines Product Portfolio
6.5.5 Charles River Laboratories Recent Developments/Updates
6.6 VBI Vaccines Inc
6.6.1 VBI Vaccines Inc Company Information
6.6.2 VBI Vaccines Inc Description and Business Overview
6.6.3 VBI Vaccines Inc Virus like Particle (VLP) Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 VBI Vaccines Inc Virus like Particle (VLP) Vaccines Product Portfolio
6.6.5 VBI Vaccines Inc Recent Developments/Updates
6.7 Creative Biostructure
6.7.1 Creative Biostructure Company Information
6.7.2 Creative Biostructure Description and Business Overview
6.7.3 Creative Biostructure Virus like Particle (VLP) Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Creative Biostructure Virus like Particle (VLP) Vaccines Product Portfolio
6.7.5 Creative Biostructure Recent Developments/Updates
6.8 WuXi Biologics
6.8.1 WuXi Biologics Company Information
6.8.2 WuXi Biologics Description and Business Overview
6.8.3 WuXi Biologics Virus like Particle (VLP) Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 WuXi Biologics Virus like Particle (VLP) Vaccines Product Portfolio
6.8.5 WuXi Biologics Recent Developments/Updates
6.9 Creative Diagnostics
6.9.1 Creative Diagnostics Company Information
6.9.2 Creative Diagnostics Description and Business Overview
6.9.3 Creative Diagnostics Virus like Particle (VLP) Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Creative Diagnostics Virus like Particle (VLP) Vaccines Product Portfolio
6.9.5 Creative Diagnostics Recent Developments/Updates
6.10 Shanghai Bovax Biotechnology Co., Ltd.
6.10.1 Shanghai Bovax Biotechnology Co., Ltd. Company Information
6.10.2 Shanghai Bovax Biotechnology Co., Ltd. Description and Business Overview
6.10.3 Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolio
6.10.5 Shanghai Bovax Biotechnology Co., Ltd. Recent Developments/Updates
6.11 Junshi Biosciences
6.11.1 Junshi Biosciences Company Information
6.11.2 Junshi Biosciences Description and Business Overview
6.11.3 Junshi Biosciences Virus like Particle (VLP) Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Junshi Biosciences Virus like Particle (VLP) Vaccines Product Portfolio
6.11.5 Junshi Biosciences Recent Developments/Updates
6.12 Luye Pharma Group
6.12.1 Luye Pharma Group Company Information
6.12.2 Luye Pharma Group Description and Business Overview
6.12.3 Luye Pharma Group Virus like Particle (VLP) Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Luye Pharma Group Virus like Particle (VLP) Vaccines Product Portfolio
6.12.5 Luye Pharma Group Recent Developments/Updates
6.13 Chengdu Kanghua Biological Products Co., Ltd.
6.13.1 Chengdu Kanghua Biological Products Co., Ltd. Company Information
6.13.2 Chengdu Kanghua Biological Products Co., Ltd. Description and Business Overview
6.13.3 Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolio
6.13.5 Chengdu Kanghua Biological Products Co., Ltd. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Virus like Particle (VLP) Vaccines Industry Chain Analysis
7.2 Virus like Particle (VLP) Vaccines Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Virus like Particle (VLP) Vaccines Production Mode & Process Analysis
7.4 Virus like Particle (VLP) Vaccines Sales and Marketing
7.4.1 Virus like Particle (VLP) Vaccines Sales Channels
7.4.2 Virus like Particle (VLP) Vaccines Distributors
7.5 Virus like Particle (VLP) Vaccines Customer Analysis
8 Virus like Particle (VLP) Vaccines Market Dynamics
8.1 Virus like Particle (VLP) Vaccines Industry Trends
8.2 Virus like Particle (VLP) Vaccines Market Drivers
8.3 Virus like Particle (VLP) Vaccines Market Challenges
8.4 Virus like Particle (VLP) Vaccines Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Premas Biotech
BioAgilytix
Coriolis
Charles River Laboratories
VBI Vaccines Inc
Creative Biostructure
Wuxi Biologics
Creative Diagnostics
Shanghai Bovax Biotechnology Co., Ltd.
Junshi Biosciences
Luye Pharma Group
Chengdu Kanghua Biological Products Co.,Ltd.
AstraZeneca Group (Icosavax)
List of Tables
 Table 1. Global Virus like Particle (VLP) Vaccines Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Virus like Particle (VLP) Vaccines Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global Virus like Particle (VLP) Vaccines Market Competitive Situation by Manufacturers in 2025
 Table 4. Global Virus like Particle (VLP) Vaccines Sales (K Dose) of Key Manufacturers (2021–2026)
 Table 5. Global Virus like Particle (VLP) Vaccines Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global Virus like Particle (VLP) Vaccines Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global Virus like Particle (VLP) Vaccines Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market Virus like Particle (VLP) Vaccines Average Price (US$/Dose) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of Virus like Particle (VLP) Vaccines, Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of Virus like Particle (VLP) Vaccines, Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of Virus like Particle (VLP) Vaccines, Product Types and Applications
 Table 12. Global Key Manufacturers of Virus like Particle (VLP) Vaccines, Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Virus like Particle (VLP) Vaccines Companies by Tier (Tier 1, Tier 2, Tier 3), based on Virus like Particle (VLP) Vaccines Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Virus like Particle (VLP) Vaccines Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global Virus like Particle (VLP) Vaccines Sales by Region (K Dose), 2021–2026
 Table 18. Global Virus like Particle (VLP) Vaccines Sales Market Share by Region (2021–2026)
 Table 19. Global Virus like Particle (VLP) Vaccines Sales by Region (K Dose), 2027–2032
 Table 20. Global Virus like Particle (VLP) Vaccines Sales Market Share by Region (2027–2032)
 Table 21. Global Virus like Particle (VLP) Vaccines Revenue by Region (US$ Million), 2021–2026
 Table 22. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Region (2021–2026)
 Table 23. Global Virus like Particle (VLP) Vaccines Revenue by Region (US$ Million), 2027–2032
 Table 24. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Region (2027–2032)
 Table 25. North America Virus like Particle (VLP) Vaccines Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America Virus like Particle (VLP) Vaccines Sales by Country (K Dose), 2021–2026
 Table 27. North America Virus like Particle (VLP) Vaccines Sales by Country (K Dose), 2027–2032
 Table 28. North America Virus like Particle (VLP) Vaccines Revenue by Country (US$ Million), 2021–2026
 Table 29. North America Virus like Particle (VLP) Vaccines Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe Virus like Particle (VLP) Vaccines Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe Virus like Particle (VLP) Vaccines Sales by Country (K Dose), 2021–2026
 Table 32. Europe Virus like Particle (VLP) Vaccines Sales by Country (K Dose), 2027–2032
 Table 33. Europe Virus like Particle (VLP) Vaccines Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe Virus like Particle (VLP) Vaccines Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific Virus like Particle (VLP) Vaccines Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific Virus like Particle (VLP) Vaccines Sales by Region (K Dose), 2021–2026
 Table 37. Asia Pacific Virus like Particle (VLP) Vaccines Sales by Region (K Dose), 2027–2032
 Table 38. Asia Pacific Virus like Particle (VLP) Vaccines Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific Virus like Particle (VLP) Vaccines Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America Virus like Particle (VLP) Vaccines Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America Virus like Particle (VLP) Vaccines Sales by Country (K Dose), 2021–2026
 Table 42. Latin America Virus like Particle (VLP) Vaccines Sales by Country (K Dose), 2027–2032
 Table 43. Latin America Virus like Particle (VLP) Vaccines Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America Virus like Particle (VLP) Vaccines Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa Virus like Particle (VLP) Vaccines Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa Virus like Particle (VLP) Vaccines Sales by Country (K Dose), 2021–2026
 Table 47. Middle East and Africa Virus like Particle (VLP) Vaccines Sales by Country (K Dose), 2027–2032
 Table 48. Middle East and Africa Virus like Particle (VLP) Vaccines Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa Virus like Particle (VLP) Vaccines Revenue by Country (US$ Million), 2027–2032
 Table 50. Global Virus like Particle (VLP) Vaccines Sales (K Dose) by Type (2021–2026)
 Table 51. Global Virus like Particle (VLP) Vaccines Sales (K Dose) by Type (2027–2032)
 Table 52. Global Virus like Particle (VLP) Vaccines Sales Market Share by Type (2021–2026)
 Table 53. Global Virus like Particle (VLP) Vaccines Sales Market Share by Type (2027–2032)
 Table 54. Global Virus like Particle (VLP) Vaccines Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global Virus like Particle (VLP) Vaccines Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Type (2021–2026)
 Table 57. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Type (2027–2032)
 Table 58. Global Virus like Particle (VLP) Vaccines Price (US$/Dose) by Type (2021–2026)
 Table 59. Global Virus like Particle (VLP) Vaccines Price (US$/Dose) by Type (2027–2032)
 Table 60. Global Virus like Particle (VLP) Vaccines Sales (K Dose) by Application (2021–2026)
 Table 61. Global Virus like Particle (VLP) Vaccines Sales (K Dose) by Application (2027–2032)
 Table 62. Global Virus like Particle (VLP) Vaccines Sales Market Share by Application (2021–2026)
 Table 63. Global Virus like Particle (VLP) Vaccines Sales Market Share by Application (2027–2032)
 Table 64. Global Virus like Particle (VLP) Vaccines Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global Virus like Particle (VLP) Vaccines Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Application (2021–2026)
 Table 67. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Application (2027–2032)
 Table 68. Global Virus like Particle (VLP) Vaccines Price (US$/Dose) by Application (2021–2026)
 Table 69. Global Virus like Particle (VLP) Vaccines Price (US$/Dose) by Application (2027–2032)
 Table 70. AstraZeneca Group (Icosavax) Company Information
 Table 71. AstraZeneca Group (Icosavax) Description and Business Overview
 Table 72. AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 73. AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Product
 Table 74. AstraZeneca Group (Icosavax) Recent Developments/Updates
 Table 75. Premas Biotech Company Information
 Table 76. Premas Biotech Description and Business Overview
 Table 77. Premas Biotech Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 78. Premas Biotech Virus like Particle (VLP) Vaccines Product
 Table 79. Premas Biotech Recent Developments/Updates
 Table 80. BioAgilytix Company Information
 Table 81. BioAgilytix Description and Business Overview
 Table 82. BioAgilytix Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 83. BioAgilytix Virus like Particle (VLP) Vaccines Product
 Table 84. BioAgilytix Recent Developments/Updates
 Table 85. Coriolis Company Information
 Table 86. Coriolis Description and Business Overview
 Table 87. Coriolis Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 88. Coriolis Virus like Particle (VLP) Vaccines Product
 Table 89. Coriolis Recent Developments/Updates
 Table 90. Charles River Laboratories Company Information
 Table 91. Charles River Laboratories Description and Business Overview
 Table 92. Charles River Laboratories Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 93. Charles River Laboratories Virus like Particle (VLP) Vaccines Product
 Table 94. Charles River Laboratories Recent Developments/Updates
 Table 95. VBI Vaccines Inc Company Information
 Table 96. VBI Vaccines Inc Description and Business Overview
 Table 97. VBI Vaccines Inc Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 98. VBI Vaccines Inc Virus like Particle (VLP) Vaccines Product
 Table 99. VBI Vaccines Inc Recent Developments/Updates
 Table 100. Creative Biostructure Company Information
 Table 101. Creative Biostructure Description and Business Overview
 Table 102. Creative Biostructure Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 103. Creative Biostructure Virus like Particle (VLP) Vaccines Product
 Table 104. Creative Biostructure Recent Developments/Updates
 Table 105. WuXi Biologics Company Information
 Table 106. WuXi Biologics Description and Business Overview
 Table 107. WuXi Biologics Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 108. WuXi Biologics Virus like Particle (VLP) Vaccines Product
 Table 109. WuXi Biologics Recent Developments/Updates
 Table 110. Creative Diagnostics Company Information
 Table 111. Creative Diagnostics Description and Business Overview
 Table 112. Creative Diagnostics Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 113. Creative Diagnostics Virus like Particle (VLP) Vaccines Product
 Table 114. Creative Diagnostics Recent Developments/Updates
 Table 115. Shanghai Bovax Biotechnology Co., Ltd. Company Information
 Table 116. Shanghai Bovax Biotechnology Co., Ltd. Description and Business Overview
 Table 117. Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 118. Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Product
 Table 119. Shanghai Bovax Biotechnology Co., Ltd. Recent Developments/Updates
 Table 120. Junshi Biosciences Company Information
 Table 121. Junshi Biosciences Description and Business Overview
 Table 122. Junshi Biosciences Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 123. Junshi Biosciences Virus like Particle (VLP) Vaccines Product
 Table 124. Junshi Biosciences Recent Developments/Updates
 Table 125. Luye Pharma Group Company Information
 Table 126. Luye Pharma Group Description and Business Overview
 Table 127. Luye Pharma Group Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 128. Luye Pharma Group Virus like Particle (VLP) Vaccines Product
 Table 129. Luye Pharma Group Recent Developments/Updates
 Table 130. Chengdu Kanghua Biological Products Co., Ltd. Company Information
 Table 131. Chengdu Kanghua Biological Products Co., Ltd. Description and Business Overview
 Table 132. Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 133. Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Product
 Table 134. Chengdu Kanghua Biological Products Co., Ltd. Recent Developments/Updates
 Table 135. Key Raw Materials Lists
 Table 136. Raw Materials Key Suppliers Lists
 Table 137. Virus like Particle (VLP) Vaccines Distributors List
 Table 138. Virus like Particle (VLP) Vaccines Customers List
 Table 139. Virus like Particle (VLP) Vaccines Market Trends
 Table 140. Virus like Particle (VLP) Vaccines Market Drivers
 Table 141. Virus like Particle (VLP) Vaccines Market Challenges
 Table 142. Virus like Particle (VLP) Vaccines Market Restraints
 Table 143. Research Programs/Design for This Report
 Table 144. Key Data Information from Secondary Sources
 Table 145. Key Data Information from Primary Sources
 Table 146. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Virus like Particle (VLP) Vaccines
 Figure 2. Global Virus like Particle (VLP) Vaccines Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Virus like Particle (VLP) Vaccines Market Share by Type: 2025 & 2032
 Figure 4. Prophylactic Vaccine Product Picture
 Figure 5. Therapeutic Vaccine Product Picture
 Figure 6. Global Virus like Particle (VLP) Vaccines Market Value by Application (US$ Million), 2021–2032
 Figure 7. Global Virus like Particle (VLP) Vaccines Market Share by Application: 2025 & 2032
 Figure 8. Hepatitis B Virus (HBV)
 Figure 9. Human Papillomavirus (HPV)
 Figure 10. Hepatitis E Virus (HEV)
 Figure 11. Other
 Figure 12. Global Virus like Particle (VLP) Vaccines Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 13. Global Virus like Particle (VLP) Vaccines Market Size (US$ Million), 2021–2032
 Figure 14. Global Virus like Particle (VLP) Vaccines Sales (K Dose), 2021–2032
 Figure 15. Global Virus like Particle (VLP) Vaccines Average Price (US$/Dose), 2021–2032
 Figure 16. Virus like Particle (VLP) Vaccines Report Years Considered
 Figure 17. Virus like Particle (VLP) Vaccines Sales Share by Manufacturers in 2025
 Figure 18. Global Virus like Particle (VLP) Vaccines Revenue Share by Manufacturers in 2025
 Figure 19. Top 5 and Top 10 Global Virus like Particle (VLP) Vaccines Players: Market Share by Revenue in Virus like Particle (VLP) Vaccines in 2025
 Figure 20. Virus like Particle (VLP) Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 21. Global Virus like Particle (VLP) Vaccines Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 22. North America Virus like Particle (VLP) Vaccines Sales Market Share by Country (2021–2032)
 Figure 23. North America Virus like Particle (VLP) Vaccines Revenue Market Share by Country (2021–2032)
 Figure 24. United States Virus like Particle (VLP) Vaccines Revenue Growth Rate (US$ Million), 2021–2032
 Figure 25. Canada Virus like Particle (VLP) Vaccines Revenue Growth Rate (US$ Million), 2021–2032
 Figure 26. Europe Virus like Particle (VLP) Vaccines Sales Market Share by Country (2021–2032)
 Figure 27. Europe Virus like Particle (VLP) Vaccines Revenue Market Share by Country (2021–2032)
 Figure 28. Germany Virus like Particle (VLP) Vaccines Revenue Growth Rate (US$ Million), 2021–2032
 Figure 29. France Virus like Particle (VLP) Vaccines Revenue Growth Rate (US$ Million), 2021–2032
 Figure 30. U.K. Virus like Particle (VLP) Vaccines Revenue Growth Rate (US$ Million), 2021–2032
 Figure 31. Italy Virus like Particle (VLP) Vaccines Revenue Growth Rate (US$ Million), 2021–2032
 Figure 32. Russia Virus like Particle (VLP) Vaccines Revenue Growth Rate (US$ Million), 2021–2032
 Figure 33. Asia Pacific Virus like Particle (VLP) Vaccines Sales Market Share by Region (2021–2032)
 Figure 34. Asia Pacific Virus like Particle (VLP) Vaccines Revenue Market Share by Region (2021–2032)
 Figure 35. China Virus like Particle (VLP) Vaccines Revenue Growth Rate (US$ Million), 2021–2032
 Figure 36. Japan Virus like Particle (VLP) Vaccines Revenue Growth Rate (US$ Million), 2021–2032
 Figure 37. South Korea Virus like Particle (VLP) Vaccines Revenue Growth Rate (US$ Million), 2021–2032
 Figure 38. India Virus like Particle (VLP) Vaccines Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. Australia Virus like Particle (VLP) Vaccines Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. China Taiwan Virus like Particle (VLP) Vaccines Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. Southeast Asia Virus like Particle (VLP) Vaccines Revenue Growth Rate (US$ Million), 2021–2032
 Figure 42. Latin America Virus like Particle (VLP) Vaccines Sales Market Share by Country (2021–2032)
 Figure 43. Latin America Virus like Particle (VLP) Vaccines Revenue Market Share by Country (2021–2032)
 Figure 44. Mexico Virus like Particle (VLP) Vaccines Revenue Growth Rate (US$ Million), 2021–2032
 Figure 45. Brazil Virus like Particle (VLP) Vaccines Revenue Growth Rate (US$ Million), 2021–2032
 Figure 46. Argentina Virus like Particle (VLP) Vaccines Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. Colombia Virus like Particle (VLP) Vaccines Revenue Growth Rate (US$ Million), 2021–2032
 Figure 48. Middle East and Africa Virus like Particle (VLP) Vaccines Sales Market Share by Country (2021–2032)
 Figure 49. Middle East and Africa Virus like Particle (VLP) Vaccines Revenue Market Share by Country (2021–2032)
 Figure 50. Turkey Virus like Particle (VLP) Vaccines Revenue Growth Rate (US$ Million), 2021–2032
 Figure 51. Saudi Arabia Virus like Particle (VLP) Vaccines Revenue Growth Rate (US$ Million), 2021–2032
 Figure 52. UAE Virus like Particle (VLP) Vaccines Revenue Growth Rate (US$ Million), 2021–2032
 Figure 53. Global Sales Market Share of Virus like Particle (VLP) Vaccines by Type (2021–2032)
 Figure 54. Global Revenue Market Share of Virus like Particle (VLP) Vaccines by Type (2021–2032)
 Figure 55. Global Virus like Particle (VLP) Vaccines Price (US$/Dose) by Type (2021–2032)
 Figure 56. Global Sales Market Share of Virus like Particle (VLP) Vaccines by Application (2021–2032)
 Figure 57. Global Revenue Market Share of Virus like Particle (VLP) Vaccines by Application (2021–2032)
 Figure 58. Global Virus like Particle (VLP) Vaccines Price (US$/Dose) by Application (2021–2032)
 Figure 59. Virus like Particle (VLP) Vaccines Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Novocure

SIMILAR REPORTS

VLP Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Virus Like Particles Market Research Report 2024
VLP based Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Vaccination Device Market Research Report 2024
Global Seasonal Vaccines Market Research Report 2024
Global Adult Vaccines Market Research Report 2024
Global Poultry Viral Disease Vaccines Market Research Report 2024
Global Monkeypox Virus Vaccine Market Research Report 2024
Global Viral Vector Vaccines Market Insights Forecast to 2030
Global Vaccines for the Elderly Market Research Report 2024
Global Live Vaccines Market Research Report 2024
Global Glass Vial for Vaccine Market Research Report 2024
Global Virus like Particles VLPs Delivery System Market Research Report 2024
Virus like Particle VLP Service Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Virus like Particles VLPs Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Fully Liquid Pentavalent Vaccine Market Research Report 2024
Global HIV Vaccine Market Research Report 2025
Global Pneumococcal Polysaccharide Vaccine Market Research Report 2024
Global Viral Vectors Market Research Report 2024
Global Electric Vaccine Vehicle Market Research Report 2025
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions